Primary Objective
• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.
Secondary Objectives
* To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.
Adults ≥18 years of age.
Endoscopically confirmed LA grade B, C, or D reflux esophagitis.
GERD symptoms (heartburn, regurgitation) for at least 4 weeks prior to enrollment.
Willing to provide informed consent and comply with study procedures.
Previous or ongoing treatment with Vonaprazan or Esomeprazole in the last 4 weeks.
Prior esophageal surgery or radiation therapy.
Barrett's esophagus, esophageal stricture, or malignancy.
Pregnant or breastfeeding women.